Trump says Europe does one thing right: drug prices. ‘A pill that costs $10 in London costs $130 in New York or Los Angeles’

At Davos President Trump touted an executive order and a 'most favored nation' policy and a deal with 17 pharmaceutical companies intended to slash U.S. drug prices—he even claimed a recent pledge to cut prices by up to 90%—while alleging he pressured France with a threatened 25% tariff. Independent data temper the policy's near-term impact: a 2024 RAND study found U.S. drug prices averaged 2.78x those in 33 countries, but a January 2026 46brooklyn report and 3 Axis Advisors data show participating firms raised prices on hundreds of branded drugs (median hike ~4%), suggesting the reforms are creating geopolitical and regulatory risk for pharma profits but so far limited immediate relief for U.S. consumers.

Analysis

Market structure: US policy signaling (most-favored-nation, executive orders) shifts pricing power away from manufacturers toward payers and regulators. Winners: insurers/PBMs with lower net drug spend and non-U.S. global pharma that can reallocate volumes; losers: US-centric branded biotechs and companies with >40% revenue from high-margin US Rx pricing. Expect downward pressure on gross margins of large-cap pharma by 5–15% over 12–24 months if realized across classes.

Risk assessment: Tail risks include aggressive statutory price caps, compulsory licensing, or cross-border reciprocity that could cut US pharma profits >20% and force R&D reallocation outside the US; litigation and trade retaliation are medium-probability. Immediate impact (days–weeks): headline-driven equity volatility; short-term (2–6 months): price adjustments, corporate repricing and Qs; long-term (1–3 years): lower new-drug launches and altered capex/R&D allocation.

Trade implications: Favor long payers/managed-care (insurers) and diversified non-US pharma (NVS) while trimming exposure to US mid/small-cap biotech and single-product franchises (e.g., AbbVie-style assets). Use relative-value: long UNH, short IBB/XBI or AbbVie to capture margin reallocation. Volatility in pharma names argues for buying puts on concentrated US pharma exposure and using bonds (TLT) as inflation/deflation hedge.

Contrarian: Consensus assumes modest, margin-nibbling deals; miss is that opaque rebate mechanics allow companies to offset cuts by raising list prices elsewhere or accelerating launches—short squeeze risk if pricing deals are watered down. Reaction is likely underdone in insurers and overdone in small-cap biotech; historical parallel: 2018 drug-pricing headlines caused multi-quarter underperformance in small biotech but selective rebounds when rules stalled. Monitor HHS/CMS rule text and 10-K revenue geography within 30–60 days.

Key Decisions for Investors

• Establish a 2–3% long position in UNH (UnitedHealth) over 6–12 months; thesis: lower net drug costs improve medical loss ratio and EPS expansion of 5–10% annualized. Set stop-loss at -8% and take-profit +15% or on a positive 2Q premium guide.
• Initiate a 1.5–2% short exposure to biotech risk via long 3-month put options on IBB (iShares NASDAQ Biotechnology ETF) ~10% OTM, or short IBB outright; rationale: concentrated US pricing exposure and high beta to policy headlines. Cover if HHS final rule is non-binding or within 60 days if price increases by issuers exceed +4% median.
• Buy NVS (Novartis) 1–2% long as a defensive pharma holding with global pricing optionality; pair trade by shorting ABBV (AbbVie) 1:1 for 3–9 months to capture relative resilience—close pair if ABBV reports <5% Y/Y revenue decline tied to pricing or biosimilar erosion.
• Allocate 1–2% to TLT (long 10yr Treasury ETF) as a hedge for downside inflation/deflation if subsequent CPI prints drop >0.1% MoM or if HHS/CMS actions materially lower medical inflation expectations within next 3 months.